These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16211657)

  • 1. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
    Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
    Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
    Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
    Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
    Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
    Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F
    Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
    Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
    Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library.
    Schmid B; Warnecke A; Fichtner I; Jung M; Kratz F
    Bioconjug Chem; 2007; 18(6):1786-99. PubMed ID: 17915955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
    Chung DE; Kratz F
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5157-63. PubMed ID: 16875815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.
    Elsadek B; Graeser R; Warnecke A; Unger C; Saleem T; El-Melegy N; Madkor H; Kratz F
    ACS Med Chem Lett; 2010 Aug; 1(5):234-8. PubMed ID: 24900200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
    Warnecke A; Fichtner I; Sass G; Kratz F
    Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
    DeFeo-Jones D; Garsky VM; Wong BK; Feng DM; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Wai J; Senderak ET; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Freidinger R; Huff J; Oliff A; Jones RE
    Nat Med; 2000 Nov; 6(11):1248-52. PubMed ID: 11062536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
    Kratz F; Ehling G; Kauffmann HM; Unger C
    Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
    Ravel D; Dubois V; Quinonero J; Meyer-Losic F; Delord J; Rochaix P; Nicolazzi C; Ribes F; Mazerolles C; Assouly E; Vialatte K; Hor I; Kearsey J; Trouet A
    Clin Cancer Res; 2008 Feb; 14(4):1258-65. PubMed ID: 18281561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.
    Warnecke A; Kratz F
    Bioconjug Chem; 2003; 14(2):377-87. PubMed ID: 12643748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
    Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
    J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
    Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
    Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.